The cell-mediated adaptive immune response to herpes simplex virus type 1 encephalitis: mechanisms and clinical implications
-
By
-
Louise Osborne
-
Cordelia Dunai
-
Yun Huang
-
Franklyn N. Egbe
-
Lance Turtle
-
Benedict D. Michael
-
Mark A. Ellul
-
July 10, 2026
-
Clinical Scorecard: Cell-Mediated Immunity in Herpes Simplex Virus Type 1 Encephalitis: Mechanisms and Clinical Significance
At a Glance
| Category | Detail |
|---|
| Condition | Herpes Simplex Encephalitis |
| Key Mechanisms | Cell-mediated immunity involving CD8+, CD4+, and brain tissue-resident memory T cells; inflammatory response impacting neuroglial injury. |
| Target Population | Individuals with HSV-1 infection, particularly children and adults over 50. |
| Care Setting | Clinical management of viral encephalitis |
Key Highlights
- HSV-1 is the most common sporadic cause of viral encephalitis worldwide.
- Aciclovir has reduced mortality from 75% to around 15-20%.
- 40-60% of survivors experience long-term neurological sequelae.
- Cell-mediated immunity can both protect against and exacerbate neuroglial injury.
- Immunosuppressive treatments may increase susceptibility to HSV encephalitis.
Guideline-Based Recommendations
Diagnosis
- Clinical features include fever, seizures, headache, and reduced consciousness.
Management
- Use of aciclovir as the primary antiviral treatment.
Monitoring & Follow-up
- Clinical vigilance for patients on immunosuppressive treatments.
Risks
- Impaired cell-mediated immunity may predispose individuals to HSE.
Patient & Prescribing Data
Patients with HSV-1 infection, especially those with compromised immune systems.
Consider adjunctive neuroprotective treatments and immunomodulatory strategies.
Clinical Best Practices
- Monitor for neurological sequelae in survivors of HSE.
- Assess immune status in patients with HSV-1 infection.
Related Resources & Content
